Effect of ezetimibe/simvastatin (EZE/SIM) versus SIM monotherapy on the lipid profile of hypercholesterolemic (HC) patients with metabolic syndrome (MetS)

被引：0
|
作者：
Feldman, T
Zakson-Aiken, M
Shah, A
MacCubbin, D
Tribble, D
Veltri, E
Michel, Y
机构：
来源：
DIABETES | 2005年 / 54卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A148 / A148
页数：1
相关论文
共 46 条
  • [1] Effect of ezetimibe/simvastatin versus simvastatin monotherapy on the lipid profile of hypercholesterolemic patients with metabolic syndrome
    Ose, L
    Feldman, T
    Zakson-Aiken, M
    Shah, A
    Maccubbin, D
    Tribble, D
    Veltri, E
    Mitchel, Y
    DIABETOLOGIA, 2005, 48 : A393 - A393
  • [2] The Effects of Ezetimibe/Simvastatin versus Simvastatin Monotherapy on Platelet and Inflammatory Biomarkers in Patients with Metabolic Syndrome
    Miller, Michael
    DiNicolantonio, James J.
    Can, Mehmet
    Grice, Rachel
    Damoulakis, Abigail
    Serebruany, Victor L.
    CARDIOLOGY, 2013, 125 (02) : 74 - 77
  • [3] Effects of coadministered ezetimibe (EZE) and fenofibrate (FENO) in mixed dyslipidemic patients with metabolic syndrome (METS)
    Bays, Harold E.
    Davies, Michael
    Shah, Arvind
    MacDonell, Geraldine
    Gumbiner, Barry
    DIABETES, 2006, 55 : A519 - A519
  • [4] Evaluation of ezetimibe/simvastatin versus rosuvastatin in hypercholesterolemic patients with type 2 diabetes or metabolic syndrome
    Ballantyne, Christie M.
    Davidson, Michael H.
    Catapano, Alberico L.
    Brady, William E.
    Gazzara, Russell A.
    Tershakovec, Andrew
    DIABETES, 2006, 55 : A520 - A520
  • [5] Ezetimibe/Simvastatin Versus Atorvastatin in Metabolic Syndrome Patients with Hypercholesterolemia
    Robinson, Jennifer G.
    Ballantyne, Christie M.
    Grundy, Scott M.
    Hsueh, Willa
    Parving, Hans-Henrik
    Rosen, Jeffrey B.
    Adewale, Adeniyi J.
    Polis, Adam B.
    Tomassini, Joanne E.
    Tershakovec, Andrew M.
    DIABETES, 2009, 58 : A181 - A181
  • [6] Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients
    Catapano, Alberico L.
    Davidson, Michael H.
    Ballantyne, Christie M.
    Brady, William E.
    Gazzara, Russell A.
    Tomassini, Joanne E.
    Tershakovec, Andrew M.
    CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (10) : 2041 - 2053
  • [7] EZETIMIBE/SIMVASTATIN (E/S) VS ATORVASTATIN (A) IN PATIENTS WITH HYPERCHOLESTEROLEMIA (HC) AND METABOLIC SYNDROME (METS) GROUPED BY PRESENCE OF ATHEROSCLEROTIC VASCULAR DISEASE (AVD)
    Robinson, J.
    Ballantyne, C.
    Grundy, S.
    Hsueh, W.
    Parving, H.
    Rosen, J.
    Shah, A.
    Hanson, M.
    Tomassini, J.
    Tershakovec, A.
    ATHEROSCLEROSIS SUPPLEMENTS, 2009, 10 (02)
  • [8] Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with metabolic syndrome.
    Masana, L
    Tonkon, M
    Simons, L
    Lee, M
    Maccubbin, D
    Gumbiner, B
    DIABETOLOGIA, 2003, 46 : A75 - A75
  • [9] Effects of ezetimibe added-to on-going statin therapy on the lipid profile of hypercholesterolemic patients with metabolic syndrome
    Tonkon, M
    Simons, L
    Lee, M
    MacCubbin, D
    Gumbiner, B
    DIABETES, 2003, 52 : A214 - A214
  • [10] EZETIMIBE/SIMVASTATIN (E/S) VS ATORVASTATIN (A) IN METABOLIC SYNDROME (MS) PATIENTS WITH HYPERCHOLESTEROLEMIA (HC)
    Robinson, J.
    Ballantyne, C.
    Grundy, S.
    Hsueh, W.
    Parving, H-H
    Rosen, J.
    Adewale, A.
    Polis, A.
    Tomassini, J.
    Tershakovec, A.
    ATHEROSCLEROSIS SUPPLEMENTS, 2009, 10 (02)
12345